Cannabinoid receptor 2 signaling in neurodegenerative disorders: From pathogenesis to a promising therapeutic target

Frontiers in Neuroscience

Volumn 11, Issue FEB, 2017, Pages

  Cassano, Tommaso ^a   Calcagnini, Silvio ^b   Pace, Lorenzo ^a   Marco, Federico De ^c   Romano, Adele ^b   Gaetani, Silvana ^b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Alzheimer's disease; Astrocytes; Microglia; Neuroinflammation; Neuroprotection; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; FATTY ACID AMIDASE;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG TARGETING; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; MODULATION; MOLECULAR MECHANICS; NERVE CELL DEGENERATION; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; PARKINSON DISEASE; PATHOGENESIS; SHORT SURVEY; UPREGULATION;

EID: 85014415619     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2017.00030     Document Type: Short Survey

References (125)

1. Arroyo, D. S., Soria, J. A., Gaviglio, E. A., Rodriguez-Galan, M. C., and Iribarren, P. (2011). Toll-like receptors are key players in neurodegeneration. Int. Immunopharmacol. 11, 1415-1421. doi: 10.1016/j.intimp.2011.05.006
2. Aureli, C., Cassano, T., Masci, A., Francioso, A., Martire, S., Cocciolo, A., et al. (2014). 5-S-cysteinyldopamine neurotoxicity: influence on the expression of a-synuclein and ERp57 in cellular and animal models of Parkinson's disease. J. Neurosci. Res. 92, 347-358. doi: 10.1002/jnr.23318
3. Austin, S. A., Floden, A. M., Murphy, E. J., and Combs, C. K. (2006). Alpha-synuclein expression modulates microglial activation phenotype. J. Neurosci. 26, 10558-10563. doi: 10.1523/JNEUROSCI.1799-06.2006
4. Bartels, A. L., and Leenders, K. L. (2009). Parkinson's disease: the syndrome, the pathogenesis and pathophysiology. Cortex 45, 915-921. doi: 10.1016/j.cortex.2008.11.010
5. Bedse, G., Romano, A., Cianci, S., Lavecchia, A. M., Lorenzo, P., Elphick, M. R., et al. (2014). Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of Alzheimer's disease. J. Alzheimers. Dis. 40, 701-712. doi: 10.3233/JAD-131910
6. Bedse, G., Romano, A., Lavecchia, A. M., Cassano, T., and Gaetani, S. (2015). The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease. J. Alzheimers. Dis. 43, 1115-1136. doi: 10.3233/JAD-141635
7. Benito, C., Núñez, E., Tolón, R. M., Carrier, E. J., Rábano, A., Hillard, C. J., et al. (2003). Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 23, 11136-11141.
8. Benito, C., Tolón, R. M., Pazos, M. R., Núñez, E., Castillo, A. I., and Romero, J. (2008). Cannabinoid CB2 receptors in human brain inflammation. Br. J. Pharmacol. 153, 277-285. doi: 10.1038/sj.bjp.0707505
9. Benveniste, E. N., Nguyen, V. T., and Wesemann, D. R. (2004). Molecular regulation of CD40 gene expression in macrophages and microglia. Brain Behav. Immun. 18, 7-12. doi: 10.1016/j.bbi.2003.09.001
10. Bonnet, A. E., and Marchalant, Y. (2015). Potential therapeutical contributions of the endocannabinoid system towards aging and Alzheimer's disease. Aging Dis. 6, 400-405. doi: 10.14336/AD.2015.0617
11. Branchi, I., D'Andrea, I., Armida, M., Carnevale, D., Ajmone-Cat, M. A., Pèzzola, A., et al. (2010). Striatal 6-OHDA lesion in mice: investigating early neurochemical changes underlying Parkinson's disease. Behav. Brain Res. 208, 137-143. doi: 10.1016/j.bbr.2009.11.020
12. Branchi, I., D'Andrea, I., Armida, M., Cassano, T., Pèzzola, A., Potenza, R. L., et al. (2008). Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J. Neurosci. Res. 86, 2050-2061. doi: 10.1002/jnr.21642
13. Brown, S. M., Wager-Miller, J., and Mackie, K. (2002). Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochim. Biophys. Acta 1576, 255-264. doi: 10.1016/S0167-4781(02)00341-X
14. Buckley, N. E., McCoy, K. L., Mezey, E., Bonner, T., Zimmer, A., Felder, C. C., et al. (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol. 396, 141-149. doi: 10.1016/S0014-2999(00)00211-9
15. Cabral, G. A., and Griffin-Thomas, L. (2009). Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert. Rev. Mol. Med. 11:e3. doi: 10.1017/S1462399409000957
16. Callén, L., Moreno, E., Barroso-Chinea, P., Moreno-Delgado, D., Cortés, A., Mallol, J., et al. (2012). Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J. Biol. Chem. 287, 20851-20865. doi: 10.1074/jbc. M111.335273
17. Calne, D., Schulzer, M., Mak, E., and Stoessl, A. J. (2005). Treatment for the progression of Parkinson's disease. Lancet Neurol. 4, 206. doi: 10.1016/S1474-4422(05)70026-0
18. Carroll, C. B., Bain, P. G., Teare, L., Liu, X., Joint, C., Wroath, C., et al. (2004). Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 63, 1245-1250. doi: 10.1212/01.WNL.0000140288.48796.8E
19. Cassano, T., Pace, L., Bedse, G., Lavecchia, A. M., De Marco, F., Gaetani, S., et al. (2016). Glutamate and mitochondria: two prominent players in the oxidative stress-induced neurodegeneration. Curr. Alzheimer Res. 13, 185-197. doi: 10.2174/1567205013666151218132725
20. Cassano, T., Serviddio, G., Gaetani, S., Romano, A., Dipasquale, P., Cianci, S., et al. (2012). Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease. Neurobiol. Aging 33, 1121.e1-12. doi: 10.1016/j.neurobiolaging.2011.09.021
21. Chen, B., Bromley-Brits, K., He, G., Cai, F., Zhang, X., and Song, W. (2010). Effect of synthetic cannabinoid HU210 on memory deficits and neuropathology in Alzheimer's disease mouse model. Curr. Alzheimer Res. 7, 255-261. doi: 10.2174/156720510791050948
22. Churcher, I. (2006). Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr. Top. Med. Chem. 6, 579-595. doi: 10.2174/156802606776743057
23. Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., and Gilula, N. B. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-87. doi: 10.1038/384083a0
24. D'Addario, C., Micioni Di Bonaventura, M. V., Pucci, M., Romano, A., Gaetani, S., Ciccocioppo, R., et al. (2014). Endocannabinoid signaling and food addiction. Neurosci. Biobehav. Rev. 47:203-224. doi: 10.1016/j.neubiorev.2014.08.008
25. de Lau, L. M., and Breteler, M. M. (2006). Epidemiology of Parkinson's disease. Lancet Neurol. 5, 525-535. doi: 10.1016/S1474-4422(06)70471-9
26. Denora, N., Cassano, T., Laquintana, V., Lopalco, A., Trapani, A., Cimmino, C. S., et al. (2012). Novel codrugs with GABAergic activity for dopamine delivery in the brain. Int. J. Pharm. 437, 221-231. doi: 10.1016/j.ijpharm.2012.08.023
27. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949. doi: 10.1126/science.1470919
28. Di Gioia, S., Trapani, A., Mandracchia, D., De Giglio, E., Cometa, S., Mangini, V., et al. (2015). Intranasal delivery of dopamine to the striatum using glycol chitosan/sulfobutylether-β-cyclodextrin based nanoparticles. Eur. J. Pharm. Biopharm. 94, 180-193. doi: 10.1016/j.ejpb.2015.05.019
29. Di Iorio, G., Lupi, M., Sarchione, F., Matarazzo, I., Santacroce, R., Petruccelli, F., et al. (2013). The endocannabinoid system: a putative role in neurodegenerative diseases. Int. J. High Risk Behav. Addict. 2, 100-106. doi: 10.5812/ijhrba.9222
30. Di Marzo, V., Stella, N., and Zimmer, A. (2015). Endocannabinoid signalling and the deteriorating brain. Nat. Rev. Neurosci. 16, 30-42. doi: 10.1038/nrn3876
31. Dinh, T. P., Freund, T. F., and Piomelli, D. (2002). A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem. Phys. Lipids. 121, 149-158. doi: 10.1016/S0009-3084(02)00150-0
32. Duan, Y., Dong, S., Gu, F., Hu, Y., and Zhao, Z. (2012). Advances in the pathogenesis of Alzheimer's disease: focusing on tau-mediated neurodegeneration. Transl. Neurodegener. 1:24. doi: 10.1186/2047-9158-1-24
33. Egertová, M., Cravatt, B. F., and Elphick, M. R. (2003). Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119, 481-496. doi: 10.1016/S0306-4522(03)00145-3
34. Ehrhart, J., Obregon, D., Mori, T., Hou, H., Sun, N., Bai, Y., et al. (2005). Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation. 2:29. doi: 10.1186/1742-2094-2-29
35. Elphick, M. R., and Egertová, M. (2005). The phylogenetic distribution and evolutionary origins of endocannabinoid signalling. Handb. Exp. Pharmacol. 168, 283-297. doi: 10.1007/3-540-26573-2_9
36. Esposito, G., Iuvone, T., Savani, C., Scuderi, C., De Filippis, D., Papa, M., et al. (2007). Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence. J. Pharmacol. Exp. Ther. 322, 1144-1152. doi: 10.1124/jpet.107.121566
37. Fagan, S. G., and Campbell, V. A. (2014). The influence of cannabinoids on generic traits of neurodegeneration. Br. J. Pharmacol. 171, 1347-1360. doi: 10.1111/bph.12492
38. Fakhfouri, G., Ahmadiani, A., Rahimian, R., Grolla, A. A., Moradi, F., and Haeri, A. (2012). WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway. Neuropharmacology 63, 653-666. doi: 10.1016/j.neuropharm.2012.05.013
39. Fernández-Ruiz, J., García, C., Sagredo, O., Gómez-Ruiz, M., and de Lago, E. (2010). The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin. Ther. Targets 14, 387-404. doi: 10.1517/14728221003709792
40. Fernández-Ruiz, J., Moro, M. A., and Martínez-Orgado, J. (2015). Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications. Neurotherapeutics 12, 793-806. doi: 10.1007/s13311-015-0381-7
41. Freund, T. F., Katona, I., and Piomelli, D. (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83, 1017-1066. doi: 10.1152/physrev.00004.2003
42. Gao, H. M., Kotzbauer, P. T., Uryu, K., Leight, S., Trojanowski, J. Q., and Lee, V. M. (2008). Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J. Neurosci. 28, 7687-7698. doi: 10.1523/JNEUROSCI.0143-07.2008
43. García, C., Palomo-Garo, C., García-Arencibia, M., Ramos, J., Pertwee, R., and Fernández-Ruiz, J. (2011). Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease. Br. J. Pharmacol. 163, 1495-1506. doi: 10.1111/j.1476-5381.2011.01278.x
44. García-Arencibia, M., García, C., Kurz, A., Rodríguez-Navarro, J. A., Gispert-Sáchez, S., Mena, M. A., et al. (2009). Cannabinoid CB1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of specific park genes. J. Neural. Transm. Suppl. 73, 269-275. doi: 10.1007/978-3-211-92660-4_22
45. García-Arencibia, M., González, S., de Lago, E., Ramos, J. A., Mechoulam, R., and Fernández-Ruiz, J. (2007). Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoids receptor-independent properties. Brain Res. 1134, 162-170. doi: 10.1016/j.brainres.2006.11.063
46. Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., et al. (2006). In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 21, 404-412. doi: 10.1016/j.nbd.2005.08.002
47. Gómez-Gálvez, Y., Palomo-Garo, C., Fernández-Ruiz, J., and García, C. (2016). Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 64, 200-208. doi: 10.1016/j.pnpbp.2015.03.017
48. Griffin, G., Tao, Q., and Abood, M. E. (2000). Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J. Pharmacol. Exp. Ther. 292, 886-894.
49. Grünblatt, E., Bartl, J., Zehetmayer, S., Ringel, T. M., Bauer, P., Riederer, P., et al. (2009). Gene expression as peripheral biomarkers for sporadic Alzheimer's disease. J. Alzheimers. Dis. 16, 627-634. doi: 10.3233/JAD-2009-0996
50. Halleskog, C., Mulder, J., Dahlström, J., Mackie, K., Hortobágyi, T., Tanila, H., et al. (2011). WNT signaling in activated microglia is proinflammatory. Glia 59, 119-131. doi: 10.1002/glia.21081
51. Halliday, G. M., and Stevens, C. H. (2011). Glia: initiators and progressors of pathology in Parkinson's disease. Mov. Disord. 26, 6-17. doi: 10.1002/mds.23455
52. Horti, A. G., Gao, Y., Ravert, H. T., Finley, P., Valentine, H., Wong, D. F., et al. (2010). Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg. Med. Chem. 18, 5202-5207. doi: 10.1016/j.bmc.2010.05.058
53. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., et al. (2002). International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 161-202. doi: 10.1124/pr.54.2.161
54. Jimenez-Del-Rio, M., Daza-Restrepo, A., and Velez-Pardo, C. (2008). The cannabinoid CP55, 940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: implications in Parkinson's disease. Neurosci. Res. 61, 404-411. doi: 10.1016/j.neures.2008.04.011
55. Kalifa, S., Polston, E. K., Allard, J. S., and Manaye, K. F. (2011). Distribution patterns of cannabinoid CB1 receptors in the hippocampus of APPswe/PS1ΔE9 double transgenic mice. Brain Res. 1376, 94-100. doi: 10.1016/j.brainres.2010.12.061
56. Klegeris, A., Bissonnette, C. J., and McGeer, P. L. (2003). Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br. J. Pharmacol. 139, 775-786. doi: 10.1038/sj.bjp.0705304
57. Klegeris, A., Pelech, S., Giasson, B. I., Maguire, J., Zhang, H., McGeer, E. G., et al. (2008). Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol. Aging 29, 739-752. doi: 10.1016/j.neurobiolaging.2006.11.013
58. Klein, T. W., Newton, C., Larsen, K., Lu, L., Perkins, I., Nong, L., et al. (2003). The cannabinoid system and immune modulation. J. Leukoc. Biol. 74, 486-496. doi: 10.1189/jlb.0303101
59. Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., et al. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108. doi: 10.1038/ng0298-106
60. Lastres-Becker, I., Cebeira, M., de Ceballos, M. L., Zeng, B. Y., Jenner, P., Ramos, J. A., et al. (2001). Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. J. Neurosci. 14, 1827-1832. doi: 10.1046/j.0953-816x.2001.01812.x
61. Liu, Q. R., Pan, C. H., Hishimoto, A., Li, C. Y., Xi, Z. X., Llorente-Berzal, A., et al. (2009). Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav. 8, 519-530. doi: 10.1111/j.1601-183X.2009.00498.x
62. Lu, H. C., and Mackie, K. (2015). An introduction to the endogenous cannabinoid system. Biol. Psychiatry 79, 516-525. doi: 10.1016/j.biopsych.2015.07.028
63. Maccarrone, M., Bari, M., Battista, N., Di Rienzo, M., and Finazzi-Agrò, A. (2001). Endogenous cannabinoids in neuronal and immune cells: toxic effects, levels and degradation. Funct. Neurol. 16(4 Suppl.), 53-60.
64. Maccarrone, M., Dainese, E., and Oddi, S. (2010). Intracellular trafficking of anandamide: new concepts for signaling. Trends Biochem. Sci. 35, 601-608. doi: 10.1016/j.tibs.2010.05.008
65. Mackie, K. (2005). Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol. 168, 299-325. doi: 10.1007/3-540-26573-2_10
66. Manuel, I., González de San Román, E., Giralt, M. T., Ferrer, I., and Rodríguez-Puertas, R. (2014). Type-1 cannabinoid receptor activity during Alzheimer's disease progression. J. Alzheimers. Dis. 42, 761-766. doi: 10.3233/JAD-140492
67. Marsicano, G., Moosmann, B., Hermann, H., Lutz, B., and Behl, C. (2002). Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J. Neurochem. 80, 448-456. doi: 10.1046/j.0022-3042.2001.00716.x
68. Martin-Moreno, A. M., Brera, B., Spuch, C., Carro, E., García-García, L., Delgado, M., et al. (2012). Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J. Neuroinflammation. 9:8. doi: 10.1186/1742-2094-9-8
69. McGeer, P. L., Itagaki, S., Boyes, B. E., and McGeer, E. G. (1988). Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285-1291. doi: 10.1212/WNL.38.8.1285
70. McGeer, P. L., McGeer, E. G., and Yasojima, K. (2000). Alzheimer disease and neuroinflammation. J. Neural Transm. Suppl. 59, 53-57. doi: 10.1007/978-3-7091-6781-6_8
71. McPartland, J., Di Marzo, V., De Petrocellis, L., Mercer, A., and Glass, M. (2001). Cannabinoid receptors are absent in insects. J. Comp. Neurol. 436, 423-429. doi: 10.1002/cne.1078
72. Mecha, M., Carrillo-Salinas, F. J., Feliú, A., Mestre, L., and Guaza, C. (2016). Microglia activation states and cannabinoid system: therapeutic implications. Pharmacol. Ther. 166:40-55. doi: 10.1016/j.pharmthera.2016.06.011
73. Mechoulam, R. (1970). Marihuana chemistry. Science 168, 1159-1166. doi: 10.1126/science.168.3936.1159
74. Mechoulam, R. (2005). Plant cannabinoids: a neglected pharmacological treasure trove. Br. J. Pharmacol. 146, 913-915. doi: 10.1038/sj.bjp.0706415
75. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90. doi: 10.1016/0006-2952(95)00109-D
76. Mechoulam, R., and Gaoni, Y. (1965). A total synthesis of DL-delta-1-tetrahydrocannabinol, the active constituent of hashish. J. Am. Chem. Soc. 87, 3273-3275. doi: 10.1021/ja01092a065
77. Mechoulam, R., and Parker, L. A. (2013). The endocannabinoid system and the brain. Annu. Rev. Psychol. 64, 21-47. doi: 10.1146/annurev-psych-113011-143739
78. Micale, V., Di Marzo, V., Sulcova, A., Wotjak, C. T., and Drago, F. (2013). Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol. Ther. 138, 18-37. doi: 10.1016/j.pharmthera.2012.12.002
79. Molina-Holgado, F., Molina-Holgado, E., Guaza, C., and Rothwell, N. J. (2002). Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J. Neurosci. Res. 67, 829-836. doi: 10.1002/jnr.10165
80. Molina-Holgado, F., Pinteaux, E., Moore, J. D., Molina-Holgado, E., Guaza, C., Gibson, R. M., et al. (2003). Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci. 23, 6470-6474.
81. Morgese, M. G., Cassano, T., Cuomo, V., and Giuffrida, A. (2007). Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp. Neurol. 208, 110-119. doi: 10.1016/j.expneurol.2007.07.021
82. Morgese, M. G., Cassano, T., Gaetani, S., Macheda, T., Laconca, L., Dipasquale, P., et al. (2009). Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55, 212-2. Neurochem. Int. 54, 56-64. doi: 10.1016/j.neuint.2008.10.007
83. Mulder, J., Zilberter, M., Pasquaré, S. J., Alpár, A., Schulte, G., Ferreira, S. G., et al. (2011). Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain 134(Pt 4), 1041-1060. doi: 10.1093/brain/awr046
84. Munoz, L., and Ammit, A. J. (2010). Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology 58, 561-568. doi: 10.1016/j.neuropharm.2009.11.010
85. Nong, L., Newton, C., Friedman, H., and Klein, T. W. (2001). CB1 and CB2 receptor mRNA expression in human peripheral blood mononuclear cells (PBMC) from various donor types. Adv. Exp. Med. Biol. 493, 229-233. doi: 10.1007/0-306-47611-8_27
86. Núñez, E., Benito, C., Pazos, M. R., Barbachano, A., Fajardo, O., González, S., et al. (2004). Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 53, 208-213. doi: 10.1002/syn.20050
87. Núñez, E., Benito, C., Tolón, R. M., Hillard, C. J., Griffin, W. S., and Romero, J. (2008). Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. Neuroscience 151, 104-110. doi: 10.1016/j.neuroscience.2007.10.029
88. Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., et al. (2005). Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57, 168-175. doi: 10.1002/ana.20338
89. Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P., Di Marzo, V., Elphick, M. R., et al. (2010). International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev. 62, 588-631. doi: 10.1124/pr.110.003004
90. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047. doi: 10.1126/science.276.5321.2045
91. Price, D. A., Martinez, A. A., Seillier, A., Koek, W., Acosta, Y., Fernandez, E., et al. (2009). WIN55, 212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease. Eur. J. Neurosci. 29, 2177-2186. doi: 10.1111/j.1460-9568.2009.06764.x
92. Ramírez, B. G., Blázquez, C., Gómez del Pulgar, T., Guzmán, M., and de Ceballos, M. L. (2005). Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25, 1904-1913. doi: 10.1523/JNEUROSCI.4540-04.2005
93. Reed-Geaghan, E. G., Savage, J. C., Hise, A. G., and Landreth, G. E. (2009). CD14 and toll-like receptors 2 and 4 are required for fibrillar Aβ-stimulated microglial activation. J. Neurosci. 29, 11982-11992. doi: 10.1523/JNEUROSCI.3158-09.2009
94. Reynolds, A. D., Glanzer, J. G., Kadiu, I., Ricardo-Dukelow, M., Chaudhuri, A., Ciborowski, P., et al. (2007). Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J. Neurochem. 104, 1504-1525. doi: 10.1111/j.1471-4159.2007.05087.x
95. Reynolds, A. D., Kadiu, I., Garg, S. K., Glanzer, J. G., Nordgren, T., Ciborowski, P., et al. (2008). Nitrated alpha-synuclein and microglial neuroregulatory activities. J. Neuroimmune Pharmacol. 3, 59-74. doi: 10.1007/s11481-008-9100-z
96. Rodríguez-Cueto, C., Benito, C., Fernández-Ruiz, J., Romero, J., Hernández-Gálvez, M., and Gómez-Ruiz, M. (2014). Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias. Br. J. Pharmacol. 171, 1472-1489. doi: 10.1111/bph.12283
97. Rohn, T. T. (2010). The role of caspases in Alzheimer's disease; potential novel therapeutic opportunities. Apoptosis 15, 1403-1409. doi: 10.1007/s10495-010-0463-2
98. Saito, V. M., Wotjak, C. T., and Moreira, F. A. (2010). Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders? Revista Brasileira de Psiquiatria 32, S7-S14.
99. Sánchez, A. J., and García-Merino, A. (2012). Neuroprotective agents: cannabinoids. Clin. Immunol. 142, 57-67. doi: 10.1016/j.clim.2011.02.010
100. Sastre, M., Klockgether, T., and Heneka, M. T. (2006). Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int. J. Dev. Neurosci. 24, 167-176. doi: 10.1016/j.ijdevneu.2005.11.014
101. Serviddio, G., Romano, A. D., Cassano, T., Bellanti, F., Altomare, E., and Vendemiale, G. (2011). Principles and therapeutic relevance for targeting mitochondria in aging and neurodegenerative diseases. Curr. Pharm. Des. 17, 2036-2055. doi: 10.2174/138161211796904740
102. Sheng, W. S., Hu, S., Min, X., Cabral, G. A., Lokensgard, J. R., and Peterson, P. K. (2005). Synthetic cannabinoid WIN55, 212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49, 211-219. doi: 10.1002/glia.20108
103. Shire, D., Calandra, B., Rinaldi-Carmona, M., Oustric, D., Pessègue, B., Bonnin-Cabanne, O., et al. (1996). Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim. Biophys. Acta 1307, 132-136. doi: 10.1016/0167-4781(96)00047-4
104. Solas, M., Francis, P. T., Franco, R., and Ramirez, M. J. (2013). CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiol. Aging 34, 805-808. doi: 10.1016/j.neurobiolaging.2012.06.005
105. Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., and Goedert, M. (1998). alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 95, 6469-6473. doi: 10.1073/pnas.95.11.6469
106. Spoto, B., Fezza, F., Parlongo, G., Battista, N., Sgro', E., Gasperi, V., et al. (2006). Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie 88, 1889-1897. doi: 10.1016/j.biochi.2006.07.019
107. Stella, N. (2010). Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58, 1017-1030. doi: 10.1002/glia.20983
108. Sugiura, T., Kondo, S., Kishimoto, S., Miyashita, T., Nakane, S., Kodaka, T., et al. (2000). Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem. 275, 605-612. doi: 10.1074/jbc.275.1.605
109. Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., et al. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89-97. doi: 10.1006/bbrc.1995.2437
110. Tansey, M. G., and Goldberg, M. S. (2010). Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 37, 510-518. doi: 10.1016/j.nbd.2009.11.004
111. Taylor, J. M., Main, B. S., and Crack, P. J. (2013). Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease. Neurochem. Int. 62, 803-819. doi: 10.1016/j.neuint.2012.12.016
112. Ternianov, A., Pérez-Ortiz, J. M., Solesio, M. E., García-Gutiérrez, M. S., Ortega-álvaro, A., Navarrete, F., et al. (2012). Overexpression of CB2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine. Neurobiol. Aging 33, 421.e1-16. doi: 10.1016/j.neurobiolaging.2010.09.012
113. Thomas, M. P., Chartrand, K., Reynolds, A., Vitvitsky, V., Banerjee, R., and Gendelman, H. E. (2007). Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. J. Neurochem. 100, 503-519. doi: 10.1111/j.1471-4159.2006.04315.x
114. Trapani, A., De Giglio, E., Cafagna, D., Denora, N., Agrimi, G., Cassano, T., et al. (2011). Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. Int. J. Pharm. 419, 1296-1307. doi: 10.1016/j.ijpharm.2011.07.036
115. Turcotte, C., Blanchet, M. R., Laviolette, M., and Flamand, N. (2016). The CB(2) receptor and its role as a regulator of inflammation. Cell. Mol. Life Sci. 73, 4449-4470. doi: 10.1007/s00018-016-2300-4
116. Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., et al. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310, 329-332. doi: 10.1126/science.1115740
117. Vendel, E., and de Lange, E. C. (2014). Functions of the CB1 and CB2 receptors in neuroprotection at the level of the blood-brain barrier. Neuromol. Med. 16, 620-642. doi: 10.1007/s12017-014-8314-x
118. Viscomi, M. T., Oddi, S., Latini, L., Pasquariello, N., Florenzano, F., Bernardi, G., et al. (2009). Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J. Neurosci. 29, 4564-4570. doi: 10.1523/JNEUROSCI.0786-09.2009
119. Walsh, D. M., and Selkoe, D. J. (2004). Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44, 181-193. doi: 10.1016/j.neuron.2004.09.010
120. White, J. A., Manelli, A. M., Holmberg, K. H., Van Eldik, L. J., and Ladu, M. J. (2005). Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol. Dis. 18, 459-465. doi: 10.1016/j.nbd.2004.12.013
121. Wotherspoon, G., Fox, A., McIntyre, P., Colley, S., Bevan, S., and Winter, J. (2005). Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135, 235-245. doi: 10.1016/j.neuroscience.2005.06.009
122. Yiangou, Y., Facer, P., Durrenberger, P., Chessell, I. P., Naylor, A., Bountra, C., et al. (2006). COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 6:12. doi: 10.1186/1471-2377-6-12
123. Zarranz, J. J., Alegre, J., Gómez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., et al. (2004). The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173. doi: 10.1002/ana.10795
124. Zhang, J., Hoffert, C., Vu, H. K., Groblewski, T., Ahmad, S., and O'Donnell, D. (2003). Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur. J. Neurosci. 17, 2750-2754. doi: 10.1046/j.1460-9568.2003.02704.x
125. Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., et al. (2005). Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 19, 533-542. doi: 10.1096/fj.04-2751com